Dong-A ST Co., Ltd.

KOSE:A170900 Stock Report

Market Cap: ₩597.0b

Dong-A ST Valuation

Is A170900 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A170900 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A170900 (₩67900) is trading below our estimate of fair value (₩300218.56)

Significantly Below Fair Value: A170900 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A170900?

Key metric: As A170900 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for A170900. This is calculated by dividing A170900's market cap by their current revenue.
What is A170900's PS Ratio?
PS Ratio0.9x
Sales₩675.41b
Market Cap₩597.03b

Price to Sales Ratio vs Peers

How does A170900's PS Ratio compare to its peers?

The above table shows the PS ratio for A170900 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average2.3x
A053030 BINEX
4.6x25.2%₩560.8b
A001060 JW Pharmaceutical
0.8x9.4%₩587.6b
A019170 Shinpoong PharmaceuticalLtd
2.6xn/a₩557.7b
A086450 DongKook Pharmaceutical
1x9.4%₩724.2b
A170900 Dong-A ST
0.9x6.2%₩597.0b

Price-To-Sales vs Peers: A170900 is good value based on its Price-To-Sales Ratio (0.9x) compared to the peer average (2.2x).

Price to Sales Ratio vs Industry

How does A170900's PS Ratio compare vs other companies in the KR Pharmaceuticals Industry?

3 CompaniesPrice / SalesEstimated GrowthMarket Cap
A009290 Kwang Dong Pharmaceutical
0.1xn/aUS$146.48m
A002620 Jeil Pharma Holdings
0.2xn/aUS$91.14m
A000230 Ildong Holdings
0.1xn/aUS$56.52m
No more companies available in this PS range
A170900 0.9xIndustry Avg. 0.8xNo. of Companies15PS00.81.62.43.24+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: A170900 is expensive based on its Price-To-Sales Ratio (0.9x) compared to the KR Pharmaceuticals industry average (0.8x).

Price to Sales Ratio vs Fair Ratio

What is A170900's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A170900 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.9x
Fair PS Ratio1.9x

Price-To-Sales vs Fair Ratio: A170900 is good value based on its Price-To-Sales Ratio (0.9x) compared to the estimated Fair Price-To-Sales Ratio (1.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst A170900 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current₩67,900.00
₩91,666.67
+35.0%
5.2%₩100,000.00₩86,000.00n/a6
Nov ’25₩75,400.00
₩91,000.00
+20.7%
6.2%₩100,000.00₩83,000.00n/a6
Oct ’25₩71,200.00
₩90,800.00
+27.5%
6.7%₩100,000.00₩83,000.00n/a5
Sep ’25₩76,200.00
₩89,500.00
+17.5%
7.0%₩100,000.00₩83,000.00n/a6
Aug ’25₩71,500.00
₩88,800.00
+24.2%
8.5%₩100,000.00₩80,000.00n/a5
Jul ’25₩66,400.00
₩82,247.06
+23.9%
14.3%₩100,000.00₩63,235.29n/a5
Jun ’25₩60,400.00
₩80,957.52
+34.0%
13.7%₩100,000.00₩63,235.29n/a6
May ’25₩67,600.00
₩80,957.52
+19.8%
13.7%₩100,000.00₩63,235.29n/a6
Apr ’25₩75,700.00
₩80,957.52
+6.9%
13.7%₩100,000.00₩63,235.29n/a6
Mar ’25₩74,900.00
₩77,624.18
+3.6%
9.3%₩85,000.00₩63,235.29n/a6
Feb ’25₩68,100.00
₩72,140.52
+5.9%
6.6%₩78,431.37₩63,235.29n/a6
Jan ’25₩69,100.00
₩72,140.52
+4.4%
6.6%₩78,431.37₩63,235.29n/a6
Dec ’24₩57,549.02
₩73,039.22
+26.9%
4.4%₩78,431.37₩68,627.45n/a6
Nov ’24₩54,607.84
₩73,725.49
+35.0%
4.2%₩78,431.37₩68,627.45₩75,400.005
Oct ’24₩58,823.53
₩73,725.49
+25.3%
4.2%₩78,431.37₩68,627.45₩71,200.005
Sep ’24₩56,470.59
₩74,705.88
+32.3%
4.9%₩78,431.37₩68,627.45₩76,200.005
Aug ’24₩52,843.14
₩74,705.88
+41.4%
4.9%₩78,431.37₩68,627.45₩71,500.005
Jul ’24₩56,176.47
₩74,705.88
+33.0%
4.9%₩78,431.37₩68,627.45₩66,400.005
Jun ’24₩55,490.20
₩74,705.88
+34.6%
4.9%₩78,431.37₩68,627.45₩60,400.005
May ’24₩53,627.45
₩74,269.51
+38.5%
4.7%₩78,431.37₩68,627.45₩67,600.006
Apr ’24₩53,725.49
₩75,586.31
+40.7%
3.9%₩78,431.37₩72,087.66₩75,700.005
Mar ’24₩58,137.25
₩75,586.31
+30.0%
3.9%₩78,431.37₩72,087.66₩74,900.005
Feb ’24₩63,137.25
₩75,868.26
+20.2%
3.6%₩78,815.84₩72,087.66₩68,100.006
Jan ’24₩59,607.84
₩74,010.00
+24.2%
5.3%₩78,815.84₩67,281.81₩69,100.006
Dec ’23₩58,535.18
₩74,284.62
+26.9%
5.0%₩78,815.84₩67,281.81₩57,549.027
Nov ’23₩53,537.10
₩74,284.62
+38.8%
5.0%₩78,815.84₩67,281.81₩54,607.847

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Medy-Tox

₩847.5b

Operates as a biopharmaceutical company in South Korea.

A086900

₩125,900.00

7D

-21.7%

1Y

-39.5%

J2KBIO

₩54.3b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,510.00

7D

-25.6%

1Y

n/a

Ildong Pharmaceutical

₩339.4b

Develops, manufactures, and sells pharmaceutical products in South Korea.

A249420

₩12,150.00

7D

-7.0%

1Y

-27.7%